Arrowhead Pharmaceuticals (ARWR)
Chardan Capital analyst Keay Nakae maintained a Buy rating on Arrowhead Pharmaceuticals yesterday and set a price target of $90.00. The company’s shares closed last Monday at $80.50.
According to TipRanks.com, Nakae is a 3-star analyst with an average return of 3.0% and a 39.1% success rate. Nakae covers the Healthcare sector, focusing on stocks such as CAMP4 Therapeutics Corporation, Alto Neuroscience, Inc., and Coya Therapeutics, Inc.
Arrowhead Pharmaceuticals has an analyst consensus of Strong Buy, with a price target consensus of $89.25, an 11.9% upside from current levels. In a report issued on June 25, H.C. Wainwright also reiterated a Buy rating on the stock with a $100.00 price target.
See today’s best-performing stocks on TipRanks >>
